AR067507A1 - Estratrienos 8-beta-sustituidos como estrogeno de accion selectiva - Google Patents
Estratrienos 8-beta-sustituidos como estrogeno de accion selectivaInfo
- Publication number
- AR067507A1 AR067507A1 ARP080102978A ARP080102978A AR067507A1 AR 067507 A1 AR067507 A1 AR 067507A1 AR P080102978 A ARP080102978 A AR P080102978A AR P080102978 A ARP080102978 A AR P080102978A AR 067507 A1 AR067507 A1 AR 067507A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- alkyl
- group
- amino
- aralkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Su uso como ingredientes farmacéuticos activos que tienen una mayor afinidad in vitro por preparaciones de receptores de estrogeno de prostata de rata que por preparaciones de receptores de estrogeno de utero de rata, y que presentan una accion preferencial in vivo en el ovario en comparacion con el utero, con su produccion, su uso terapéutico, y con formas de administracion que contienen los nuevos compuestos. util para infertilidad femenina, reemplazo hormonal, artritis reumatoidea, lupus, enfermedad de Crohn, psoriasis, arteriosclerosis, endometriosis, cáncer de colon. Reivindicacion 1: Derivados de estra-1, 3, 5(10)-trieno 8beta-sustituidos CARACTERIZADOS porque son de formula general 1 donde los radicales R3, R8, R13, R16, así como R17 y R17', independientemente unos de otros, tienen el siguiente significado: R3 representa un átomo de hidrogeno o un grupo R18, donde R18 representa un radical C1-6-alquilo de cadena recta o cadena ramificada, saturado o insaturado, un grupo trifluorometilo, un radical arilo, heteroarilo o aralquilo opcionalmente sustituido con al menos un radical seleccionado independientemente entre metilo, etilo, trifluorometilo, pentafluoroetilo, trifluorometiltiol, metoxilo, etoxilo, nitro, ciano, halo, hidroxilo, amino, mono(C1-8-alquil) o di(C1-8-alquil)amino, donde ambos grupos alquilo son iguales o diferentes, di(aralquil)amino, donde ambos grupos aralquilo son iguales o diferentes, carboxilo, carboxialcoxilo, C1-20-acilo o C1-20-aciloxilo como sustituyentes; un radical acilo -C(=O)R19, donde R19 es una cadena recta o una cadena ramificada de un radical C1-C10-alquilo que está saturado o insaturado en hasta tres lugares, y que está parcialmente o completamente halogenado, o R18 representa un grupo R20SO2, donde R20 es un grupo R21R22N, donde R21 y R22, independientemente uno del otro, representan un átomo de hidrogeno, un radical C1-5-alquilo, un grupo -C(=O)R23, donde R23 representa un radical C1-10-alquilo no sustituido o sustituido, de cadena recta o cadena ramificada, que está saturado o insaturado en hasta tres lugares, y que está parcialmente o completamente halogenado, un grupo ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo o cicloheptilo, un radical C4-C15- cicloalquilalquilo con entre 3 y 7 átomos de carbono en la porcion de cicloalquilo, y con una porcion de alquilo de hasta 8 átomos de carbono, o un radical arilo, heteroarilo o aralquilo opcionalmente sustituido con al menos un radical seleccionado independientemente entre metilo, etilo, trifluorometilo, pentafluroetilo, trifluorometiltiol, metoxilo, etoxilo, nitro, ciano, halo, hidroxilo, amino, mono(C1-8-alquil) o di(C1-8-alquil) amino, donde ambos grupos alquilo son iguales o diferentes, di(aralquil)amino, donde ambos grupos aralquilo son iguales o diferentes, carboxilo, carboxialcoxilo, C1-20-acilo o C1-20-aciloxilo como sustituyentes; o junto con el átomo de N, forma un radical polimetilenimino con entre 4 y 6 átomos de carbono, o un radical morfolino, R8 es un radical alquenilo o alquinilo de cadena recta o cadena ramificada con entre 2 y 6 átomos de carbono, que opcionalmente puede estar parcialmente o completamente fluorado, R13 es un grupo metilo o un grupo etilo, R16 es un átomo de fluor en posicion alfa, R17 y R17', en cada caso independientemente uno del otros, son un átomo de hidrogeno y un grupo hidroxilo; o un átomo de hidrogeno y un grupo R18RO-, R20SO2- u OC(O)R23, donde en cada caso, R18, R20 y R23 tienen el significado que se indica bajo R3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07075600A EP2014672A1 (en) | 2007-07-12 | 2007-07-12 | 8-beta-substituted estratrienes as selectively active estrogens |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067507A1 true AR067507A1 (es) | 2009-10-14 |
Family
ID=38657613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102978A AR067507A1 (es) | 2007-07-12 | 2008-07-11 | Estratrienos 8-beta-sustituidos como estrogeno de accion selectiva |
Country Status (34)
Country | Link |
---|---|
US (1) | US20090029957A1 (es) |
EP (2) | EP2014672A1 (es) |
JP (1) | JP2010533152A (es) |
KR (1) | KR20100037593A (es) |
CN (1) | CN101687902B (es) |
AR (1) | AR067507A1 (es) |
AU (1) | AU2008274198A1 (es) |
BR (1) | BRPI0814207A2 (es) |
CA (1) | CA2692727A1 (es) |
CL (1) | CL2008002027A1 (es) |
CO (1) | CO6270230A2 (es) |
CR (1) | CR11211A (es) |
CU (1) | CU23885B1 (es) |
CY (1) | CY1113351T1 (es) |
DK (1) | DK2176282T3 (es) |
DO (1) | DOP2010000017A (es) |
EA (1) | EA017124B1 (es) |
EC (1) | ECSP109872A (es) |
ES (1) | ES2393942T3 (es) |
HN (1) | HN2010000081A (es) |
HR (1) | HRP20120952T1 (es) |
MA (1) | MA31565B1 (es) |
NZ (1) | NZ582490A (es) |
PA (1) | PA8789401A1 (es) |
PE (1) | PE20090825A1 (es) |
PL (1) | PL2176282T3 (es) |
PT (1) | PT2176282E (es) |
RS (1) | RS52541B (es) |
SI (1) | SI2176282T1 (es) |
TN (1) | TN2010000007A1 (es) |
TW (1) | TW200911824A (es) |
UA (1) | UA99918C2 (es) |
UY (1) | UY31220A1 (es) |
WO (1) | WO2009007454A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012234682A1 (en) * | 2011-03-25 | 2013-10-10 | Universite Laval | Inhibitors of 17beta-HSD1, 17beta-HSD3 and 17beta-HSD10 |
MX2019000025A (es) * | 2016-06-24 | 2019-10-30 | K&N Eng Inc | Filtro de aire compuesto. |
USD905747S1 (en) | 2018-04-09 | 2020-12-22 | Mitsubishi Electric Corporation | Display screen with animated graphical user interface |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10019167A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Ag | Substituierte Estratriene als selektiv wirksame Estrogene |
HUP0300335A2 (hu) * | 2000-04-12 | 2003-07-28 | Schering Ag. | 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
-
2007
- 2007-07-12 EP EP07075600A patent/EP2014672A1/en not_active Ceased
-
2008
- 2008-07-11 CN CN200880024423XA patent/CN101687902B/zh not_active Expired - Fee Related
- 2008-07-11 WO PCT/EP2008/059115 patent/WO2009007454A2/en active Application Filing
- 2008-07-11 CL CL2008002027A patent/CL2008002027A1/es unknown
- 2008-07-11 EP EP08775031A patent/EP2176282B1/en active Active
- 2008-07-11 PA PA20088789401A patent/PA8789401A1/es unknown
- 2008-07-11 PE PE2008001165A patent/PE20090825A1/es not_active Application Discontinuation
- 2008-07-11 KR KR1020107000527A patent/KR20100037593A/ko not_active Application Discontinuation
- 2008-07-11 DK DK08775031.1T patent/DK2176282T3/da active
- 2008-07-11 EA EA201000097A patent/EA017124B1/ru not_active IP Right Cessation
- 2008-07-11 RS RS20120516A patent/RS52541B/en unknown
- 2008-07-11 US US12/171,424 patent/US20090029957A1/en not_active Abandoned
- 2008-07-11 UA UAA201001369A patent/UA99918C2/ru unknown
- 2008-07-11 PL PL08775031T patent/PL2176282T3/pl unknown
- 2008-07-11 NZ NZ582490A patent/NZ582490A/en not_active IP Right Cessation
- 2008-07-11 AU AU2008274198A patent/AU2008274198A1/en not_active Abandoned
- 2008-07-11 SI SI200830826T patent/SI2176282T1/sl unknown
- 2008-07-11 AR ARP080102978A patent/AR067507A1/es unknown
- 2008-07-11 BR BRPI0814207-6A2A patent/BRPI0814207A2/pt not_active IP Right Cessation
- 2008-07-11 PT PT08775031T patent/PT2176282E/pt unknown
- 2008-07-11 ES ES08775031T patent/ES2393942T3/es active Active
- 2008-07-11 UY UY31220A patent/UY31220A1/es not_active Application Discontinuation
- 2008-07-11 CA CA 2692727 patent/CA2692727A1/en not_active Abandoned
- 2008-07-11 TW TW097126522A patent/TW200911824A/zh unknown
- 2008-07-11 JP JP2010515526A patent/JP2010533152A/ja not_active Ceased
-
2010
- 2010-01-07 MA MA32490A patent/MA31565B1/fr unknown
- 2010-01-07 TN TNP2010000007A patent/TN2010000007A1/fr unknown
- 2010-01-12 HN HN2010000081A patent/HN2010000081A/es unknown
- 2010-01-12 CO CO10002339A patent/CO6270230A2/es active IP Right Grant
- 2010-01-12 CR CR11211A patent/CR11211A/es not_active Application Discontinuation
- 2010-01-12 CU CU20100008A patent/CU23885B1/es not_active IP Right Cessation
- 2010-01-12 EC EC2010009872A patent/ECSP109872A/es unknown
- 2010-01-12 DO DO2010000017A patent/DOP2010000017A/es unknown
-
2012
- 2012-11-14 CY CY20121101099T patent/CY1113351T1/el unknown
- 2012-11-21 HR HRP20120952AT patent/HRP20120952T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1272505T3 (da) | 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater | |
ES2671516T3 (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
UY28157A1 (es) | Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos | |
ES2600703T3 (es) | Proceso para la producción de intermediarios de estetrol | |
SV2001000020A (es) | Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb | |
NZ609420A (en) | Fulvestrant compositions and methods of use | |
AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
AR066063A1 (es) | Derivados de triazol que son antagonistas de smo | |
AR067507A1 (es) | Estratrienos 8-beta-sustituidos como estrogeno de accion selectiva | |
ECSP067028A (es) | Profármacos de esteroides con acción androgénica | |
CR9627A (es) | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | |
UY29626A1 (es) | Moduladores no esteroides de receptores de progesterona | |
AR040188A1 (es) | Estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva | |
RU2005128831A (ru) | Обладающие противоопухолевым действием 2-замещенные эстра-1,3,5( 10 )-триен-3-илсульфаматы | |
CR9598A (es) | Moduladores no esteroides de receptor de progesterona | |
JP2010533152A5 (es) | ||
AR066234A1 (es) | Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno | |
DOP2010000200A (es) | Derivado de y-lactona de esteroide de acido 15,16-metilen-17-hidroxi-19-nor-21-carboxilico, su uso y medicamentos que contienen tal derivado | |
DOP2010000198A (es) | Derivado de y-lactona del esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y medicamento que lo contiene | |
RU2011104569A (ru) | ПРОИЗВОДНЫЕ 9α ЭСТРАТРИЕНА В КАЧЕСТВЕ ER-B СЕЛЕКТИВНЫХ ЛИГАНДОВ ДЛЯ ПРЕДОТВРАЩЕНИЯ КИШЕЧНОГО РАКА | |
UY30805A1 (es) | Moduladores no esteroides de receptores de progesterona | |
PE20061161A1 (es) | Composicion farmaceutica que comprende un esteroide | |
AR030018A1 (es) | Derivados de benzo(d)(1,3)oxazin-2-ona, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar medicamentos como moduladores receptores de progesterona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |